Skip to main content

Dr Ashish Misra, leader of the Atherosclerosis and Vascular Remodelling Unit at HRI, was recently awarded his second Perpetual IMPACT grant.

Dr Misra’s research focuses on improved understanding and potential treatment of atherosclerosis, a progressive disease where fatty plaque builds up in the arteries.

“Atherosclerosis is the main underlying cause of cardiovascular disease (CVD), which is the leading cause of death globally,” says Dr Misra.

If we could bet­ter under­stand this dev­as­tat­ing dis­ease, we could poten­tial­ly devel­op improved treat­ment meth­ods that could save thou­sands of lives worldwide.”

Dr Misra will build on his groundbreaking discovery in 2018 that changed our understanding of the way atherosclerosis progresses. Until then, smooth muscle cells (SMCs), found in the blood vessel wall, and their role in atherosclerotic plaque development were not much appreciated. Dr Misra revealed that in a developing plaque, very few ‘stem-cell like’ cells contribute to the plaque and convert into both disease-promoting and disease-protective SMC, which make plaque unstable. If unstable plaque ruptures, this could lead to heart attack.

Previous research by Dr Misra’s collaborators, Associate Professor Sanjay Patel, Coronary Diseases Group leader at HRI, and Professor Peter Thompson, University of Western Australia (UWA) Medical School, Internal Medicine, has demonstrated the protective effects of the commonly used drug colchicine to significantly reduce the risk of heart attacks. However, the mechanisms underpinning colchicine’s protective effects in CVD are virtually unknown.

Dr Misra’s recent research has now established the anti-inflammatory effects of colchicine in helping to reduce cardiovascular risk. In addition, Dr Misra has found that colchicine stabilises the diseased arteries so that they have less risk of rupturing and causing heart attack.

Supported by this new IMPACT Grant, Dr Misra will investigate the mechanisms underlying the suppressive effects of colchicine as well as combination therapies using colchicine. This will aid in further understanding how atherosclerosis advances in people, and potentially reveal more effective ways to suppress disease progression.

Devel­op­ing a low-cost, effec­tive ther­a­py for ath­er­o­scle­ro­sis would reduce CVD, includ­ing amongst those at high­est risk such as remote Indige­nous com­mu­ni­ties, and have a huge impact world­wide,” says Dr Misra.

The Perpetual IMPACT grant is funded by the Walter and Eileen Ralston Trust, and The Alma Hazel Eddy Trust.

Support HRI

Today's research is tomorrow's cure.

Every donation to the Heart Research Institute is an investment into the lives of millions. Help make a lasting difference by donating today.

Other ways you can help